

# Roger Hesselstrand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/858376/publications.pdf>

Version: 2024-02-01

72  
papers

2,503  
citations

331670

21  
h-index

214800

47  
g-index

73  
all docs

73  
docs citations

73  
times ranked

3309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.9	10
2	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization – WSF Skin Ultrasound Group. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151954.	3.4	14
3	Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2235-2248.	0.6	1
4	Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 43-49.	1.2	21
5	Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 35-42.	1.2	4
6	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	1.9	20
7	Longitudinal changes in risk status in pulmonary arterial hypertension. <i>ESC Heart Failure</i> , 2021, 8, 680-690.	3.1	8
8	Underfilling decreases left ventricular function in pulmonary arterial hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1745-1755.	1.5	9
9	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
10	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	1.9	10
11	Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 3121-3133.	1.9	60
12	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	1.9	11
13	Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2021, 61, 309-318.	1.9	8
14	Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. <i>ERJ Open Research</i> , 2021, 7, 00854-2020.	2.6	14
15	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. <i>Arthritis Research and Therapy</i> , 2021, 23, 204.	3.5	8
16	Predicting mortality during long-term follow-up in pulmonary arterial hypertension. <i>ERJ Open Research</i> , 2021, 7, 00837-2020.	2.6	20
17	N-Formyl Methionine Peptide-Mediated Neutrophil Activation in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 785275.	4.8	9
18	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	5.8	231
20	Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study. <i>Arthritis Research and Therapy</i> , 2020, 22, 230.	3.5	7
21	Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	1.7	0
22	Validity and reliability of the Patient Health Questionnaire-8 in Swedish for individuals with systemic sclerosis. <i>Rheumatology International</i> , 2020, 40, 1675-1687.	3.0	10
23	Fractional exhaled breath temperature in patients with asthma, chronic obstructive pulmonary disease, or systemic sclerosis compared to healthy controls. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1747014.	1.5	9
24	Type III, IV, and VI Collagens Turnover in Systemic Sclerosis – a Longitudinal Study. <i>Scientific Reports</i> , 2020, 10, 7145.	3.3	11
25	CMR feature tracking in cardiac asymptomatic systemic sclerosis: Clinical implications. <i>PLoS ONE</i> , 2019, 14, e0221021.	2.5	18
26	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
27	Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	10
28	Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis <i>per se</i> . <i>Clinical Physiology and Functional Imaging</i> , 2019, 39, 215-225.	1.2	20
29	Nailfold capillaroscopy—how many fingers should be examined to detect abnormality?. <i>Rheumatology</i> , 2019, 58, 284-288.	1.9	19
30	Persistent elevation of fibrosis biomarker cartilage oligomeric matrix protein following hepatitis C virus eradication. <i>World Journal of Hepatology</i> , 2019, 11, 330-334.	2.0	2
31	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1032-1038.	0.9	14
32	The assessment of nailfold capillaries: comparison of dermoscopy and nailfold videocapillaroscopy. <i>Rheumatology</i> , 2018, 57, 1115-1116.	1.9	18
33	Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study. <i>SAGE Open Medicine</i> , 2018, 6, 205031211774915.	1.8	9
34	Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 625-630.	1.9	11
35	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
36	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53

#	ARTICLE	IF	CITATIONS
37	159â€fDermoscopy versus videocapillaroscopy in the assessment of nailfold capillaroscopy images in patients with systemic sclerosis and healthy controls. <i>Rheumatology</i> , 2018, 57, .	1.9	0
38	Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with preâ€capillary pulmonary hypertension. <i>ESC Heart Failure</i> , 2018, 5, 864-875.	3.1	21
39	Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 16.	1.7	26
40	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.8	3
41	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	2.0	93
42	Intra-and inter-observer reliability of nailfold videocapillaroscopy â€” A possible outcome measure for systemic sclerosis-related microangiopathy. <i>Microvascular Research</i> , 2017, 112, 1-6.	2.5	31
43	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
44	Quantitative outcome measures for systemic sclerosis-related Microangiopathy â€” Reliability of image acquisition in Nailfold Capillaroscopy. <i>Microvascular Research</i> , 2017, 113, 56-59.	2.5	23
45	Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study. <i>Journal of Cosmetic and Laser Therapy</i> , 2017, 19, 143-148.	0.9	8
46	Information, social support and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertensionâ€”A nationwide population-based study. <i>Patient Education and Counseling</i> , 2017, 100, 936-942.	2.2	15
47	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
48	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. <i>Rheumatology</i> , 2017, 56, 844-852.	1.9	13
49	051.â€fQUANTITATIVE OUTCOME MEASURES FOR SYSTEMIC SCLEROSISâ€RELATED MICROANGIOPATHY: RELIABILITY OF IMAGE ACQUISITION IN NAILFOLD CAPILLAROSCOPY. <i>Rheumatology</i> , 2017, 56, .	1.9	0
50	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.8	1
51	Limited impact of fibromodulin deficiency on the development of experimental skin fibrosis. <i>Experimental Dermatology</i> , 2016, 25, 558-561.	2.9	4
52	Characteristics and survival of adult Swedish PAH and CTEPH patients 2000â€2014. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 243-250.	1.2	104
53	The Modified Hand Mobility in Scleroderma Test and Skin Involvement â€” A Followup Study. <i>Journal of Rheumatology</i> , 2016, 43, 1356-1362.	2.0	5
54	Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. <i>Arthritis Research and Therapy</i> , 2016, 18, 267.	3.5	44

#	ARTICLE	IF	CITATIONS
55	Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C. <i>Infectious Diseases</i> , 2015, 47, 915-918.	2.8	13
56	Airway resistance and reactance are affected in systemic sclerosis. <i>European Clinical Respiratory Journal</i> , 2015, 2, 28667.	1.5	16
57	High frequency ultrasound of skin involvement in systemic sclerosis – a follow-up study. <i>Arthritis Research and Therapy</i> , 2015, 17, 329.	3.5	28
58	Chronic Obstructive Pulmonary Disease Is Common in Never-smoking Patients with Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015, 42, 464-471.	2.0	17
59	Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2100-2107.	1.9	28
60	Work Disability in Early Systemic Sclerosis: A Longitudinal Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1794-1800.	2.0	11
61	Development of a Modified Hand Mobility in Scleroderma (HAMIS) Test and its Potential as an Outcome Measure in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 2186-2192.	2.0	21
62	Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 223-233.	1.2	18
63	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
64	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	6.5	170
65	Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2014, 8, CCRPM.S18586.	0.9	10
66	Absence of fibromodulin affects matrix composition, collagen deposition and cell turnover in healthy and fibrotic lung parenchyma. <i>Scientific Reports</i> , 2014, 4, 6383.	3.3	18
67	Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. <i>Respiratory Medicine</i> , 2013, 107, 1079-1086.	2.9	53
68	Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R215.	3.5	14
69	Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease. <i>Rheumatology</i> , 2012, 51, 915-920.	1.9	25
70	A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. <i>Rheumatology</i> , 2012, 51, 749-755.	1.9	65
71	The validity and reliability of the Swedish version of the Satisfaction with appearance scale for individuals with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832211078.	1.7	0
72	Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension. <i>ESC Heart Failure</i> , 0, , .	3.1	1